Adicet Bio Q3 net loss narrows, raises $74.8 mln

ADICET Bio

05/11/2025 21:21

Overview

Adicet Bio Q3 net loss narrows to $26.9 mln from $30.5 mln, with reduced operating expenses

Positive preliminary data from Phase 1 trial of ADI-001 in lupus nephritis and SLE

Company raises $74.8 mln in direct offering, extending cash runway into 2H 2027

Outlook

Company plans FDA meeting in 1Q/2026 for pivotal ADI-001 trial design

Adicet to submit regulatory filing for ADI-212 in 1Q/2026

Company extends cash runway into 2H/2027 following capital raise

Result Drivers

R&D EXPENSES - R&D expenses fell to $22.9 mln from $26.3 mln due to lower payroll, lab supplies, CDMO and R&D consultation costs

CAPITAL RAISE - Co raised $74.8 mln in direct offering, extending cash runway into 2H/2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$26.86 mln
Q3 Basic EPS
-$0.29
Q3 Operating Expenses
$27.95 mln
Q3 Operating Income
-$27.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adicet Bio Inc is $6.50, about 89.4% above its November 4 closing price of $0.69

Press Release: ID:nBw5G8ky1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)